High Evidence
Research Overview
HMG Research for Male Hypogonadotropic Hypogonadism
An evidence-based overview of research examining HMG in the context of male hypogonadotropic hypogonadism. This page synthesizes findings from peer-reviewed literature.
Research Summary
FDA-approved indication. Combined hCG/HMG therapy achieves spermatogenesis in 92% of men with hypogonadotropic hypogonadism. Treatment typically begins with hCG to restore testosterone, then adds HMG to stimulate spermatogenesis via Sertoli cell FSH receptors.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. HMG may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.